Skip to main content
See every side of every news story
Published loading...Updated

Decades of Studies Link Suicide Risk With Common Hair Loss Treatment

Research from Israel shows finasteride users face significant risks of mood disorders and suicide, with experts urging regulatory reassessment and improved post-approval safety studies.

  • Last month, a new Israeli study published in The Journal of Clinical Psychiatry found patients using finasteride face higher risks of mood disorders and suicidal thoughts.
  • Regulatory records show patient reports of Post‑Finasteride Syndrome surfaced in the early 2000s, while internal FDA experts allegedly advised suicide warnings rejected until decades later despite 18 suicides recorded by 2011.
  • Clinical reports add that animal studies show brain inflammation and hippocampus changes, persistent patient symptoms include insomnia and suicidal thoughts, and independent analyses highlight increased psychiatric outcomes.
  • Professor Mayer Brezis is calling to suspend finasteride marketing for cosmetic use until independent safety reviews are completed, while Organon defends product safety and urges patients and healthcare providers to discuss concerns as regulators continue reviewing data.
  • Given androgenetic alopecia affects about 80 million Americans, experts call for enforced post‑approval analytical studies and testing of stevioside‑minoxidil microneedle patches as safer alternatives.
Insights by Ground AI

7 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 57% of the sources lean Right
57% Right

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Healthline broke the news in on Sunday, October 5, 2025.
Sources are mostly out of (0)
News
For You
Search
BlindspotLocal